Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer
Supportive Care in Cancer · 2026-09 · 34 (9)
DOI: 10.1007/s00520-026-11157-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 31.08.2026. Verfasst von Yoshitaka Saito und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-jo 15-chome, Te…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Exanthema. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Background
Rash is a frequently observed adverse effect of gemcitabine (GEM) plus nanoparticle albumin-bound paclitaxel (nab-PTX) therapy for pancreatic cancer. However, the clinical characteristics of this reaction remain poorly understood. In this study, we aimed to identify factors associated with the development of rash during GEM plus nab-PTX therapy for pancreatic cancer in a real-world setting.
Methods
Patients with pancreatic cancer receiving GEM plus nab-PTX ( n = 313) were retrospectively evaluated. The primary endpoint was to identify factors associated with all-grade rash during the first cycle. The secondary endpoint was the change in eosinophil levels from baseline to the nearest assessment time point after rash development in patients who developed symptoms.
Results
The incidence of all-grade rash was 20.4%, with grades 1 and 2 accounting for 18.5% and 1.9%, respectively. Multivariable logistic regression analysis identified baseline renal impairment as an independent risk factor and the regular co-administration of non-steroidal anti-inflammatory drugs (NSAIDs) as a protective factor for rash development (adjusted odds ratio [95% confidence interval]: 2.01 [1.03–3.91], P = 0.04 for renal impairment; and 0.44 [0.20–0.91], P = 0.03 for NSAID co-administration). Eosinophilia at the nearest time point after symptom onset occurred in 12.5% of patients with rash, with eosinophil levels significantly elevated from baseline, suggesting partial involvement of an immune-mediated mechanism.
Conclusion
Our study identified baseline renal impairment as a risk factor and regular NSAID co-administration as a protective factor against rash development during real-world GEM plus nab-PTX therapy for pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmaceutics & Therapeutics, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, 4-1, Maeda 7-jo 15-chome, Teine-ku, Sapporo, Hokkaido, 006-8585, Japan. saito-yo@hus.ac.jp.
- Department of Pharmacy, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
- Cancer Center, Hokkaido University Hospital, Kita 14-jo, Nishi 5-chome, Kita-ku, Sapporo, 060-8648, Japan.
- Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12-jo, Nishi 6-chome, Kita-ku, Sapporo, 060-0812, Japan.
Zitieren
APA
Saito, Y., Takekuma, Y., Komatsu, Y., & Sugawara, M. (2026). Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer. Supportive Care in Cancer, 34(9). https://doi.org/10.1007/s00520-026-11157-0
Vancouver
Saito Y, Takekuma Y, Komatsu Y, Sugawara M. Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer. Supportive Care in Cancer. 2026;34(9). doi:10.1007/s00520-026-11157-0
BibTeX
@article{Saito2026,
author = {Saito, Yoshitaka and Takekuma, Yoh and Komatsu, Yoshito and Sugawara, Mitsuru},
title = {Identification of factors associated with rash during gemcitabine plus nanoparticle albumin-bound paclitaxel treatment for pancreatic cancer},
journal = {Supportive Care in Cancer},
year = {2026},
volume = {34},
number = {9},
doi = {10.1007/s00520-026-11157-0}
}
EUVIMED